Vestibular Diseases - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：29頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Vestibular Diseases - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Vestibular Diseases - Pipeline Review, H1 2014’, provides an overview of the Vestibular Diseases’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Vestibular Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vestibular Diseases and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vestibular Diseases
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vestibular Diseases and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vestibular Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vestibular Diseases pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vestibular Diseases
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vestibular Diseases pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Vestibular Diseases - Pipeline Review, H1 2014’, provides an overview of the Vestibular Diseases’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Vestibular Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vestibular Diseases and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vestibular Diseases
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vestibular Diseases and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vestibular Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vestibular Diseases pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vestibular Diseases
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vestibular Diseases pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vestibular Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Vestibular Diseases - Overview 7
Pipeline Products for Vestibular Diseases - Comparative Analysis 8
Vestibular Diseases - Therapeutics under Development by Companies 9
Vestibular Diseases - Pipeline Products Glance 11
Early Stage Products 11
Vestibular Diseases - Products under Development by Companies 12
Vestibular Diseases - Companies Involved in Therapeutics Development 13
Quark Pharmaceuticals, Inc. 13
Griffin Discoveries BV 14
Sensorion Pharmaceuticals 15
Vestibular Diseases - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Molecule Type 19
Drug Profiles 21
siRNA for CNS Disorders - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SR-1001 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Inhibit Histamine H4 Receptor for Vestibular disorders - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SR-2001 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SENS-300 Series - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SENS-100 Series - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SENS-200 Series - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29
List of Tables
Number of Products under Development for Vestibular Diseases, H1 2014 7
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Vestibular Diseases - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 13
Vestibular Diseases - Pipeline by Griffin Discoveries BV, H1 2014 14
Vestibular Diseases - Pipeline by Sensorion Pharmaceuticals, H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 17
Number of Products by Stage and Mechanism of Action, H1 2014 18
Number of Products by Stage and Molecule Type, H1 2014 20
List of Figures
Number of Products under Development for Vestibular Diseases, H1 2014 7
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Molecule Type, H1 2014 19
Number of Products by Stage and Top 10 Molecule Type, H1 2014 20
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vestibular Diseases Overview 6
Therapeutics Development 7
Pipeline Products for Vestibular Diseases - Overview 7
Pipeline Products for Vestibular Diseases - Comparative Analysis 8
Vestibular Diseases - Therapeutics under Development by Companies 9
Vestibular Diseases - Pipeline Products Glance 11
Early Stage Products 11
Vestibular Diseases - Products under Development by Companies 12
Vestibular Diseases - Companies Involved in Therapeutics Development 13
Quark Pharmaceuticals, Inc. 13
Griffin Discoveries BV 14
Sensorion Pharmaceuticals 15
Vestibular Diseases - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Molecule Type 19
Drug Profiles 21
siRNA for CNS Disorders - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SR-1001 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecules to Inhibit Histamine H4 Receptor for Vestibular disorders - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SR-2001 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SENS-300 Series - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SENS-100 Series - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SENS-200 Series - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29
List of Tables
Number of Products under Development for Vestibular Diseases, H1 2014 7
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Vestibular Diseases - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 13
Vestibular Diseases - Pipeline by Griffin Discoveries BV, H1 2014 14
Vestibular Diseases - Pipeline by Sensorion Pharmaceuticals, H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 17
Number of Products by Stage and Mechanism of Action, H1 2014 18
Number of Products by Stage and Molecule Type, H1 2014 20
List of Figures
Number of Products under Development for Vestibular Diseases, H1 2014 7
Number of Products under Development for Vestibular Diseases - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Molecule Type, H1 2014 19
Number of Products by Stage and Top 10 Molecule Type, H1 2014 20
